List of Excipients in Branded Drug ARTHRITIS 8 HOUR

Generic Drugs Containing ARTHRITIS 8 HOUR

Company	Ingredient	NDC	Excipient
Safeway Inc	acetaminophen	21130-336	CELLULOSE, MICROCRYSTALLINE
Safeway Inc	acetaminophen	21130-336	CROSCARMELLOSE SODIUM
Safeway Inc	acetaminophen	21130-336	HYPROMELLOSES
Safeway Inc	acetaminophen	21130-336	MAGNESIUM STEARATE
Safeway Inc	acetaminophen	21130-336	POVIDONE
Safeway Inc	acetaminophen	21130-336	PROPYLENE GLYCOL

What are the Most Frequently-Used Excipients in ARTHRITIS 8 HOUR?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	HYPROMELLOSES
1	MAGNESIUM STEARATE
1	POVIDONE
1	PROPYLENE GLYCOL

Arthritis 8 Hour Excipient Strategy and Commercial Opportunities

Last updated: September 5, 2026

Arthritis 8 Hour is generally positioned as an extended-release acetaminophen product, typically 650 mg per caplet for temporary relief of arthritis pain. Its commercial value comes from dosing convenience, broad OTC access, and low manufacturing cost rather than active-ingredient exclusivity. The primary formulation challenge is controlling acetaminophen release without increasing dose confusion, tablet size, gastrointestinal burden, or manufacturing complexity.

The analysis below treats Arthritis 8 Hour as a U.S. OTC acetaminophen extended-release product. Exact inactive ingredients vary by manufacturer and National Drug Code.

What is Arthritis 8 Hour and how is it regulated?

Arthritis 8 Hour products typically contain acetaminophen 650 mg in an extended-release caplet. The usual adult directions for comparable products are two caplets every eight hours, with a maximum of six caplets in 24 hours.[1]

Product attribute	Typical profile
Active ingredient	Acetaminophen
Strength	650 mg per extended-release caplet
Dosage form	Film-coated caplet or tablet
OTC status	Nonprescription
Primary indication	Temporary relief of minor aches and pains, including arthritis pain
Dosing interval	Approximately every eight hours
Maximum daily dose	Commonly 3,900 mg under product labeling
Regulatory pathway	OTC monograph or monograph-based labeling
Orange Book status	Generally not applicable to monograph OTC products
Biosimilar exposure	None
Core commercial differentiator	Extended dosing interval

Acetaminophen is regulated under the FDA’s internal analgesic and antipyretic monograph framework, including 21 C.F.R. § 343.50.[2] The product does not depend on an FDA-approved new drug application in the same way as a prescription analgesic.

The principal regulatory risk is cumulative acetaminophen exposure. Consumers may combine an arthritis product with cold, flu, sleep, or prescription products that also contain acetaminophen. FDA labeling rules require prominent warnings concerning severe liver damage, alcohol use, and concurrent acetaminophen-containing products.[3]

What excipients protect the extended-release profile?

The commercial formulation normally uses a matrix or barrier system that slows water penetration and acetaminophen diffusion. Common excipient functions include:

Excipient function	Typical materials	Commercial purpose
Hydrophilic release matrix	Hypromellose, cellulose derivatives	Forms a hydrated gel that slows drug release
Tablet binder	Povidone, cellulose, starch derivatives	Provides mechanical strength and compressibility
Disintegrant or pore former	Sodium starch glycolate or related materials	Controls tablet breakup and release onset
Lubricant	Magnesium stearate	Reduces sticking and ejection force
Wax or hydrophobic barrier	Carnauba wax or similar waxes	Reduces water penetration and prolongs release
Film coating	Hypromellose, polyethylene glycol, pigments	Improves swallowability, appearance, and product identification
Opacifier or colorant	Titanium dioxide or approved colorants, where used	Supports visual differentiation and branding

Comparable TYLENOL 8 HR Arthritis Pain labeling has identified inactive ingredients such as carnauba wax, cellulose, hypromellose, magnesium stearate, povidone, and sodium starch glycolate.[1] A private-label Arthritis 8 Hour product can use a different excipient system while meeting the same performance and labeling requirements.

The most important formulation variable is the ratio of acetaminophen to release-controlling polymer. Increasing polymer concentration can extend release but may increase tablet size, hardness, residual drug release, and manufacturing cost. Wax-based barriers can reduce water ingress but may produce more sensitivity to milling, coating, and compression conditions.

What excipient strategy is most commercially attractive?

A commercially efficient strategy uses a robust hydrophilic matrix with limited excipient complexity. The preferred design generally has four characteristics:

1. A high drug load suitable for a compact caplet.
2. A release profile that remains controlled across normal gastrointestinal pH conditions.
3. Standard excipients available from multiple suppliers.
4. A process compatible with high-speed direct compression or wet granulation.

Hydrophilic matrix strategy

Hypromellose-based matrices are attractive because they are widely available, scalable, and familiar to regulators and contract manufacturers. They can be adjusted by polymer viscosity, particle size, concentration, and compression force.

The principal opportunity is to optimize polymer grade and loading so that the product retains an eight-hour dosing proposition without excessive tablet mass. A lower-viscosity polymer can improve processability but may require a higher concentration. A higher-viscosity polymer can reduce excipient loading but may create slower or less reproducible release.

Hydrophobic matrix strategy

Wax, fatty-acid, or lipid barriers may deliver sustained release with lower water penetration. They can support a differentiated release profile, but process control is more difficult. Granulation temperature, wax distribution, particle size, and compression conditions can affect dissolution.

A hydrophobic system can be commercially useful where the manufacturer seeks a distinctive release profile or a formulation platform for multiple strengths. It has less value when the objective is the lowest-cost private-label product.

Multiparticulate strategy

Pellets, coated granules, or minitablets can provide tighter release control and reduce sensitivity to tablet compression. They may also permit combination products or flexible dose architecture.

The commercial disadvantage is higher manufacturing cost, more complex equipment, and greater analytical burden. Multiparticulates are more attractive for premium branded products than for mass-market store brands.

What formulation patents protect Arthritis 8 Hour products?

No meaningful patent moat generally protects the acetaminophen active ingredient. Acetaminophen has been commercially available for decades, and basic acetaminophen compositions are no longer a reliable source of exclusivity.

Potential protectable subject matter includes:

• Specific extended-release matrix compositions.
• Polymer ratios and particle-size distributions.
• Coated granules or multiparticulate systems.
• Dissolution profiles defined at multiple pH conditions.
• Manufacturing processes that improve content uniformity or release control.
• Abuse-deterrent or tamper-resistant dosage forms.
• Packaging systems that reduce accidental duplicate dosing.
• Combination products involving acetaminophen and another active ingredient.

For an OTC monograph product, a formulation patent would usually be separate from the regulatory listing. The product would not ordinarily have an Orange Book patent listing in the same manner as an NDA product.[4]

A patent covering only a conventional hypromellose-acetaminophen matrix may face validity and obviousness pressure if the claims broadly recite familiar excipients and expected release behavior. Stronger claims would require measured dissolution limits, unusual excipient interactions, a narrow process window, or unexpected performance.

When does Arthritis 8 Hour lose exclusivity?

Arthritis 8 Hour generally has no meaningful drug exclusivity period comparable to a new prescription medicine. The commercial position is based on branding, distribution, product recognition, packaging, and formulation execution.

Exclusivity category	Relevance to Arthritis 8 Hour
New chemical entity exclusivity	Not applicable
New drug exclusivity	Usually not applicable to monograph OTC acetaminophen
Orphan exclusivity	Not applicable
Pediatric exclusivity	Not generally relevant
Orange Book patent exclusivity	Usually not applicable
Trademark protection	Potentially relevant to brand name and trade dress
Formulation patent	Potentially relevant, but scope depends on claims
Trade-secret protection	Relevant to process parameters and supplier specifications

The active ingredient is exposed to immediate generic and private-label competition. A manufacturer cannot normally prevent other companies from selling acetaminophen extended-release products merely by owning a brand name.

What is the Orange Book status of Arthritis 8 Hour?

The product is generally outside the standard Orange Book framework when sold under the OTC monograph pathway rather than an approved prescription NDA. Orange Book listings focus on approved drug products and patents submitted under the Hatch-Waxman framework.[4]

This has several consequences:

• No conventional Orange Book patent listing should be assumed.
• Paragraph IV certification is generally not the principal challenge mechanism.
• Generic applicants do not necessarily follow an ANDA pathway for the monograph product.
• Commercial entry can occur through an OTC monograph-compliant product, subject to applicable FDA requirements.
• A private-label product may compete without challenging an Orange Book-listed patent.

What Paragraph IV challenges and litigation risks exist?

Paragraph IV litigation risk is limited because the relevant commercial product is generally an OTC monograph product rather than an NDA product with listed patents.

The more realistic legal risks are:

• Patent infringement claims directed to a specific extended-release formulation.
• Trade dress or trademark disputes involving brand presentation.
• False or misleading claims concerning duration of relief.
• Manufacturing deviations that affect dissolution or dose uniformity.
• Product liability claims involving liver injury or duplicate acetaminophen use.
• Regulatory action involving noncompliant labeling or packaging.

A formulation patent can still generate litigation if its claims cover a commercially necessary release profile. The absence of Orange Book listing does not eliminate patent risk; it changes the entry and enforcement pathway.

What generic entry risks exist for Arthritis 8 Hour?

Generic and store-brand entry risk is high. Acetaminophen is inexpensive, widely sourced, and familiar to contract manufacturers. Retailers can introduce private-label products with similar strength, dosing interval, and packaging architecture.

The major entry barriers are operational rather than legal:

• Achieving reproducible eight-hour dissolution.
• Preventing dose dumping.
• Maintaining caplet integrity during coating and shipping.
• Managing acetaminophen content uniformity at high drug loading.
• Meeting child-resistant and tamper-evident packaging requirements.
• Avoiding label confusion with immediate-release acetaminophen.
• Demonstrating stability across temperature and humidity conditions.

A challenger does not need to duplicate every excipient. It needs a compliant product with an acceptable release profile, stable manufacturing process, and commercially credible labeling.

How does Arthritis 8 Hour compare with competing pain products?

Product category	Typical dosing interval	Primary advantage	Key weakness
Acetaminophen ER 650 mg	About 8 hours	No NSAID mechanism; broad consumer familiarity	Liver toxicity risk at excessive total exposure
Immediate-release acetaminophen	4-6 hours	Low-cost, simple formulation	More frequent dosing
Ibuprofen products	4-6 hours, depending on product	Anti-inflammatory activity	Gastrointestinal, renal, and cardiovascular restrictions
Naproxen sodium	About 12 hours	Longer dosing interval and anti-inflammatory activity	Longer NSAID exposure and safety limitations
Topical diclofenac	Product-dependent	Local delivery with lower systemic exposure than oral NSAIDs	Not suitable for all pain locations or users
Combination analgesics	Variable	Potentially stronger symptom relief	Greater interaction and safety complexity

The strongest commercial position for Arthritis 8 Hour is among consumers who want longer dosing intervals but cannot or do not want to use NSAIDs. The product competes less on pharmacologic novelty than on safety perception, convenience, trust, and shelf placement.

What commercial opportunities exist for excipient innovation?

Premium extended-release positioning

A manufacturer can seek premium pricing through a smaller caplet, smoother release, easier swallowing, or reduced tablet burden. These benefits can support branded or retailer-exclusive products.

Senior-friendly dosage forms

Arthritis consumers are often older adults who may have dysphagia, polypharmacy, or reduced dexterity. Opportunities include:

• Smaller-caplet designs.
• High-contrast packaging.
• Easy-open but child-resistant closures.
• Clearly separated acetaminophen warnings.
• Unit-dose blister packs.
• Calendarized dosing systems.

A liquid or chewable extended-release form would be technically more difficult but could address consumers unable to swallow caplets.

Lower-cost private-label supply

The most immediate opportunity is contract manufacturing for pharmacy, grocery, club, and e-commerce brands. A standardized matrix platform can support multiple customers with limited changes to the active formulation.

Combination and adjacent products

Potential extensions include arthritis pain plus sleep, acetaminophen plus topical analgesic kits, and co-packaged products that address pain and mobility. Combination products increase commercial value but create additional regulatory, compatibility, and safety requirements.

Sustainable excipient and packaging systems

Reduced coating weight, recyclable bottles, lower-plastic blister systems, and supplier diversification can lower cost and improve retailer acceptance. Sustainability claims must be supported by verifiable packaging and lifecycle data.

How strong is the patent estate for Arthritis 8 Hour?

The likely patent estate is weak at the active-ingredient level and potentially moderate at the formulation level. Strength depends on whether claims cover a narrow, reproducible dissolution profile that competitors cannot readily design around.

Estate component	Likely strength
Acetaminophen composition	Weak or expired
Basic extended-release tablet	Weak to moderate
Specific polymer and wax ratios	Moderate if narrowly claimed
Manufacturing process	Moderate where process-dependent performance is demonstrated
Packaging and dosing system	Usually weak to moderate
Brand and trade dress	Potentially valuable commercially, but separate from formulation patent rights
Trade secrets	Potentially important for process parameters and supplier controls

The most defensible commercial assets are likely brand equity, retail distribution, manufacturing consistency, and packaging execution rather than broad composition claims.

What manufacturing and intellectual-property barriers matter most?

The critical manufacturing barrier is dissolution reproducibility. Acetaminophen has a high dose requirement, leaving limited room for excipients. Small changes in granule density, polymer hydration, tablet hardness, or coating integrity can alter release.

Key controls include:

• Granule particle-size distribution.
• Blend uniformity.
• Polymer viscosity and substitution grade.
• Compression force and tablet porosity.
• Coating weight gain.
• Dissolution testing across relevant pH conditions.
• Stability testing under accelerated and long-term conditions.
• Supplier qualification for polymers, lubricants, and waxes.

Trade secrets can provide practical protection even when patent protection is limited. These may include excipient preconditioning, granulation endpoint, lubrication time, compression settings, and coating parameters.

Key Takeaways

• Arthritis 8 Hour is generally an extended-release acetaminophen 650 mg OTC product.
• Its principal excipient challenge is achieving reliable eight-hour release at a high drug load.
• Hypromellose, cellulose derivatives, povidone, sodium starch glycolate, magnesium stearate, and waxes are common functional choices, but exact excipients vary by NDC.
• The active ingredient has no meaningful modern exclusivity barrier.
• Orange Book listings and Paragraph IV litigation are generally not central to monograph OTC competition.
• Generic and private-label entry risk is high.
• Strongest commercial opportunities are private-label supply, senior-friendly packaging, smaller caplets, process optimization, and premium convenience positioning.
• The most durable competitive assets are manufacturing know-how, brand recognition, retailer access, and compliant packaging.
• Formulation patents can matter, but broad conventional matrix claims are more vulnerable than narrow claims tied to measured dissolution performance.

FAQs

Can Arthritis 8 Hour use the same excipients as immediate-release acetaminophen?

It can use several of the same fillers, binders, lubricants, and coating materials, but it requires a release-control system. Immediate-release excipients alone will not reliably deliver an eight-hour profile.

Is hypromellose required for an Arthritis 8 Hour formulation?

No. Hypromellose is a common matrix polymer, but manufacturers can use waxes, lipid barriers, coated granules, alternative cellulose derivatives, or multiparticulate systems.

Does an Arthritis 8 Hour product require an ANDA?

Not necessarily. A product marketed under the applicable OTC monograph framework may follow monograph-based requirements rather than an ANDA pathway. The regulatory route depends on the product’s formulation, labeling, claims, and market status.

Can a competitor patent a new acetaminophen extended-release tablet?

Yes. A competitor may pursue formulation, process, dissolution-profile, or packaging claims. Patentability depends on novelty, non-obviousness, adequate disclosure, and claim scope.

What is the most attractive commercial format for a new entrant?

A private-label 650 mg extended-release caplet with validated dissolution performance, senior-friendly labeling, low tablet size, and flexible packaging is the lowest-risk entry format. Premium multiparticulate or specialty dosage forms offer differentiation but require higher development and manufacturing investment.

References

1. DailyMed. (n.d.). TYLENOL 8 HR arthritis pain acetaminophen extended-release tablet, film coated: Drug label. U.S. National Library of Medicine.
2. Electronic Code of Federal Regulations. (n.d.). 21 C.F.R. § 343.50: Labeling of orally administered analgesic, antipyretic, and antirheumatic drug products sold over the counter.
3. U.S. Food and Drug Administration. (2011). Prescription acetaminophen products to be limited to 325 mg per dosage unit; boxed warning will highlight potential for severe liver failure.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.